U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Mg
Molecular Weight 24.305
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MAGNESIUM

SMILES

[Mg]

InChI

InChIKey=RSHAOIXHUHAZPM-UHFFFAOYSA-N
InChI=1S/Mg.2H

HIDE SMILES / InChI

Molecular Formula Mg
Molecular Weight 24.305
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Magnesium diamide is used as a chemical intermediate. Magnesium diamide is spontaneously combustible. It is toxic by inhalation. Skin or eye contact may cause severe burns.

Originator

Curator's Comment: Ulex, a Swedish geologist, is generally credited with introduction of the term struvite in1845

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Preventing
MAGNESIUM SULFATE

Approved Use

INDICATIONS AND USAGE Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose.

Launch Date

1995
Primary
MAGNESIUM SULFATE

Approved Use

INDICATIONS AND USAGE Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose.

Launch Date

1995
Diagnostic
ColPrep Kit

Approved Use

INDICATIONS AND USAGE ColPrep Kit is indicated for cleansing of the colon as a preparation for colonoscopy in adults

Launch Date

2016
Primary
MAGNESIUM SULFATE

Approved Use

INDICATIONS AND USAGE Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose.

Launch Date

1995
Curative
MagMin

Approved Use

Magnesium aspartate (MagMin) is indicated for patients with documented hypomagnesaemia.
Curative
DELBIASE

Approved Use

Unknown
Primary
DELBIASE

Approved Use

Unknown
Primary
DELBIASE

Approved Use

Unknown
Curative
Magnesium Chloride

Approved Use

Magnesium Chloride injection is indicated as an electrolyte replenisher in magnesium deficiencies
Palliative
Magnesium Chloride

Approved Use

Unknown
Palliative
Magnesium Chloride

Approved Use

Unknown
Primary
EPIMAG

Approved Use

Magnesium citrate is indicated in cases of oxaluria, to prevent recurrence of calcium oxalate kidney stones.
Primary
EPIMAG

Approved Use

Used to relief of occasional constipation (irregularity).
Curative
Magnesium Citrate

Approved Use

Magnesium citrate is indicated to supports magnesium nutritional adequacy.
Curative
Unknown

Approved Use

Magnesium lactate is a naturally occurring mineral that is needed in the body to support the function of the heart, nervous system, and digestive system. Magnesium lactate is used as a mineral supplement to treat magnesium deficiency.
PubMed

PubMed

TitleDatePubMed
Antenatal Exposure to Magnesium Sulfate and Spontaneous Intestinal Perforation and Necrotizing Enterocolitis in Extremely Preterm Neonates.
2017-10
Fast sono assisted ferrofluid mediated silver super - Adsorption over magnesium ferrite-copper sulfide chalcogenide with the aid of multivariate optimization.
2017-07
Effect of power ultrasound on crystallization characteristics of magnesium ammonium phosphate.
2017-05
Magnesium lactate in the treatment of Gitelman syndrome: patient-reported outcomes.
2017-03-01
Superiority of a Split-dose Regimen of Sodium Picosulfate/Magnesium Citrate (SPMC) in Comparison to a Prior-day Schedule (AM/PM) for Colonoscopy Preparation. A Randomized Single-blinded Study.
2016-09
Preparation and optimization of a drug delivery system based on berberine chloride-immobilized MgAl hydrotalcite.
2016-06-15
Polyethylene glycol plus ascorbic acid is as effective as sodium picosulfate with magnesium citrate for bowel preparation: A randomized trial.
2016-04
Micronized Organic Magnesium Salts Enhance Opioid Analgesia in Rats.
2016
Single-day sodium picosulfate and magnesium citrate versus split-dose polyethylene glycol for bowel cleansing prior to colonoscopy: A prospective randomized endoscopist-blinded trial.
2015-11
Randomized controlled trial of low-volume bowel preparation agents for colonic bowel preparation: 2-L polyethylene glycol with ascorbic acid versus sodium picosulfate with magnesium citrate.
2015-02
A comparison of oral sulfate solution with sodium picosulfate: magnesium citrate in split doses as bowel preparation for colonoscopy.
2014-12
No effect of magnesium supplementation on metabolic control and insulin sensitivity in type 2 diabetic patients with normomagnesemia.
2014-09-10
Precipitation of amorphous magnesium ammonium phosphate: is it a precursor for staghorn stones?
2014-06
Effects of three kinds of organic acids on phosphorus recovery by magnesium ammonium phosphate (MAP) crystallization from synthetic swine wastewater.
2014-04
[The effectiveness of certain magnesium salts in nephrolithiasis caused by the use of sodium oxalate and celecoxib].
2013-05-14
Effect of magnesium lactate dihydrate and calcium lactate monohydrate on 20-km cycling time trial performance.
2012-04
Magnesium chloride tetrahydrate, MgCl2·4H2O.
2012-01
Increased expression of glucose transporter 3 in gerbil brains following magnesium sulfate treatment and focal cerebral ischemic injury.
2010-06
Intradermal administration of magnesium sulphate and magnesium chloride produces hypesthesia to mechanical but hyperalgesia to heat stimuli in humans.
2009-08-28
Formation of formal disilene fluoride adducts.
2008-12-24
An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence.
2006-04
Synthesis of a non-heme template for attaching four peptides: an approach to artificial iron(II)-containing peroxidases.
2004-01-23
Magnesium bromide mediated highly diastereoselective heterogeneous hydrogenation of olefins.
2002-04-18
Oral magnesium load test in patients with migraine.
2002-02
Bioavailability of US commercial magnesium preparations.
2001-12
Trifluoromethanesulfonic anhydride-promoted alpha-bromination of ketones with grignard reagent or magnesium bromide.
2000-12
An efficient chiral moderator prepared from inexpensive (+)-3-carene: synthesis of the HIV-1 non-nucleoside reverse transcriptase inhibitor DPC 963.
2000-10-05
Effect of chronic magnesium supplementation on magnesium distribution in healthy volunteers evaluated by 31P-NMRS and ion selective electrodes.
1999-11
Some magnesium salts and a mixture of magnesium and calcium salts accelerate skin barrier recovery.
1999-10
Struvite stones.
1999
Magnesium supplementation in patients with congestive heart failure.
1997-02
Conventional and Eccentric Uses of Crystallographic Databases in Practical Materials Identification Problems.
1996-01-01
Inhibition of mouse-killing behaviour in magnesium-deficient rats: effect of pharmacological doses of magnesium pidolate, magnesium aspartate, magnesium lactate, magnesium gluconate and magnesium chloride.
1995-03
Effect of pyridoxine and magnesium on stress-induced gastric ulcers in mice selected for low or high blood magnesium levels.
1995
Magnesium sulfate in the treatment of ventricular arrhythmias due to digoxin toxicity.
1995
A prospective randomized trial of intravenous magnesium versus intravenous propranolol in acute myocardial infarction.
1994-12
Accidental cardiopulmonary arrest following magnesium sulphate overdose.
1994-06-15
Management of eclampsia.
1994-04
Oral versus intravenous magnesium supplementation in patients with magnesium deficiency.
1991-01-01
Magnesium and its combination with cinnarizine in the long-term treatment of headache.
1991
Osteoporosis treated with magnesium lactate.
1991
Fluorimetry of selenium in body fluids after digestion with nitric acid, magnesium nitrate hexahydrate, and hydrochloric acid.
1988-09
A comparison of two digestion procedures for the determination of selenium in biological material.
1987-10
Metabolism of magnesium and zinc in patients treated with antiepileptic drugs and with magnesium lactate.
1987
Effects of the intravenous administration of magnesium sulfate on corrected serum calcium level and nephrogenous cyclic AMP excretion in normal human subjects.
1986-11
Hypomagnesaemic tetany associated with prolonged treatment with aminoglycosides.
1986-03-22
[Inhibitory effect of magnesium on the vocalization and fighting of cats treated with carbachol and eserine].
1982
Cardiopulmonary arrest due to acute maternal hypermagnesaemia.
1981-05-09
Struvite stones.
1978-05
Metabolic effects of prolonged intravenous administration of magnesium lactate to the normal human.
1958-09-23
Patents

Patents

Sample Use Guides

Magnesium lactate is used as a dietary supplement (200-400 mg of elemental magnesium per day for adults).
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Magnesium Chloride
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:20:16 GMT 2025
Edited
by admin
on Mon Mar 31 18:20:16 GMT 2025
Record UNII
I38ZP9992A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MAGNESIUM POWDER
INCI  
INCI  
Preferred Name English
MAGNESIUM
HSDB   MI   VANDF   WHO-DD  
Systematic Name English
MAGNESIUM METALLICUM
HPUS  
Common Name English
MAGNESIUM [MI]
Common Name English
MAGNESIUM METALLICUM [HPUS]
Common Name English
MAGNESIUM [VANDF]
Common Name English
MAGNESIUM [HSDB]
Common Name English
MG
Common Name English
Magnesium [WHO-DD]
Common Name English
Classification Tree Code System Code
LOINC 29365-4
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 17236-1
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 29364-7
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 57998-7
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 13474-2
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 29912-3
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 2596-5
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 2597-3
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 87469-3
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 2595-7
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 35252-6
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 57367-5
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 55938-5
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 24447-5
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 56956-6
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 42616-3
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 35249-2
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 32024-2
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
WHO-ATC A12CC01
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 2594-0
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 32329-5
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 20872-8
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 14824-7
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 57368-3
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 2598-1
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
WHO-ATC B05XA11
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 54919-6
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 2599-9
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LIVERTOX 579
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 29911-5
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 44336-6
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 10880-3
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 23891-5
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 26746-8
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 50873-9
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 11554-3
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 58995-2
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 19124-7
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 74696-6
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 33950-7
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 27210-4
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 49007-8
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 87470-1
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 19123-9
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 26708-8
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 2601-3
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
CFR 21 CFR 176.170
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 17235-3
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 9478-9
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 23892-3
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 2593-2
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 30536-7
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 21377-7
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 35250-0
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 18368-1
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 27122-1
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
CFR 21 CFR 102.23
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 30922-9
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 25954-9
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 16172-9
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 18369-9
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 52911-5
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 17237-9
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
LOINC 27255-9
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
DSLD 82 (Number of products:11063)
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
Code System Code Type Description
DAILYMED
I38ZP9992A
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
PRIMARY
HSDB
654
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
PRIMARY
FDA UNII
I38ZP9992A
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
PRIMARY
PUBCHEM
5462224
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
PRIMARY
SMS_ID
100000091621
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
PRIMARY
DRUG BANK
DB14513
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
PRIMARY
CAS
7439-95-4
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
PRIMARY
MERCK INDEX
m6987
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
PRIMARY Merck Index
ECHA (EC/EINECS)
231-104-6
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
PRIMARY
EPA CompTox
DTXSID0049658
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
PRIMARY
CFR
21 CFR 862.1495
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
PRIMARY
NCI_THESAURUS
C68264
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
PRIMARY
WIKIPEDIA
Magnesium
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
PRIMARY
MESH
D008274
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
PRIMARY
CHEBI
25107
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
PRIMARY
WIKIPEDIA
Magnesium (medical use)
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
PRIMARY
RXCUI
6574
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
PRIMARY RxNorm
EVMPD
SUB14407MIG
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
PRIMARY
NCI_THESAURUS
C1505
Created by admin on Mon Mar 31 18:20:16 GMT 2025 , Edited by admin on Mon Mar 31 18:20:16 GMT 2025
CONCEPT Dietary Supplement
Related Record Type Details
PARENT -> CONSTITUENT ALWAYS PRESENT
Related Record Type Details
ACTIVE MOIETY